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Afﬁbody molecules constitute a class of small (7 kDa) scaffold proteins that can be engineered to have
excellent tumor targeting properties. High reabsorption in kidneys complicates development of afﬁbody
molecules for radionuclide therapy. In this study, we evaluated the inﬂuence of the composition of
cysteine-containing C-terminal peptide-based chelators on the biodistribution and renal retention of
188Re-labeled anti-HER2 afﬁbody molecules. Biodistribution of afﬁbody molecules containing GGXC or
GXGC peptide chelators (where X is G, S, E or K) was compared with biodistribution of a parental afﬁbody
molecule ZHER2:2395 having a KVDC peptide chelator. All constructs retained low picomolar afﬁnity to
HER2-expressing cells after labeling. The biodistribution of all 188Re-labeled afﬁbody molecules was in
general comparable, with the main observed difference found in the uptake and retention of radioac-
tivity in excretory organs. The 188Re-ZHER2:V2 afﬁbody molecule with a GGGC chelator provided the
lowest uptake in all organs and tissues. The renal retention of 188Re-ZHER2:V2 (3.1 ± 0.5 %ID/g at 4 h after
injection) was 55-fold lower than retention of the parental 188Re-ZHER2:2395 (172 ± 32 %ID/g). We show
that engineering of cysteine-containing peptide-based chelators can be used for signiﬁcant improvement
of biodistribution of 188Re-labeled scaffold proteins, particularly reduction of their uptake in excretory
organs.
© 2014 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The use of monoclonal antibodies against cancer-associated
antigens improves survival of patients with disseminated cancer.
However, a substantial fraction of tumors show primary drug
resistance. Development of a secondary (acquired) resistance has
also been identiﬁed during the course of targeted therapy despite
preserved antigen expression [1e5]. Targeted radionuclide therapy
is a promising method for treatment of both inoperable primary
and disseminated antibody-resistant tumors. Several classes of
radiolabeled proteins have been used for delivery of radionuclidesion Sciences, Rudbeck Labo-
n.
. Tolmachev).
Masson SAS. This is an open accessto tumors in vivo, utilizing the speciﬁc binding of these agents to
phenotypic molecular alterations in malignant cells. In fact, tumor
targeting with radiolabeled antibodies for detection of malignancy
or for therapeutic purposes has been reported as early as the 1950's
[6,7]. However, both preclinical and clinical investigations have
revealed that the clinical effect of radioimmunotherapy (RIT) on
bulky solid tumors is limited [8]. Due to their large size (150 kDa),
radiolabeled intact antibodies are characterized by slow clearance
from blood and poor tumor penetration [8]. Several alternative
methods have been developed to overcome problems associated
with conventional RIT. The use of smaller enzymatically produced
antibody fragments [8,9], analogues of naturally existing peptide
ligands to receptors overexpressed in tumors [10], and pretargeting
strategies [11] constitute examples of new approaches aiming to
deliver radionuclides to tumors while sparing healthy tissues.
Another promising approach for the development of high afﬁnityarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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engineered scaffold proteins.
Afﬁbody molecules were one of the ﬁrst evaluated classes of
non-immunoglobulin scaffold proteins for in vivo radionuclide
targeting. These high afﬁnity ligands are based on a 58 amino acid
(7 kDa) triple a-helical scaffold derived from domain B of staphy-
lococcal protein A [12,13]. Thirteen surface located amino acids on
helices 1 and 2 have been randomized, generating large combina-
torial libraries from which afﬁbody variants targeting the desired
antigen could be selected. Due to their generally high afﬁnity to-
wards speciﬁc molecular targets and their small size, afﬁbody
molecules are attractive candidates for tumor-targeting applica-
tions [14]. An important feature is the robustness of this targeting
protein. Afﬁbody molecules typically tolerate the denaturation
during labeling procedures (e.g. exposure to high temperature or
lipophilic solvents), since they rapidly and completely refold to
their initial structure after returning to physiological conditions
[15]. This characteristic permits labeling in a pH range from 3.6 [16]
to 11.0 [17] and at temperatures up to 90 C [18], without losing
binding capacity. This allows labeling with a large variety of nu-
clides and enables to select an optimal one for each particular
application. An anti-Human Epidermal Growth Factor Receptor
type 2 (HER2) afﬁbody molecule has been extensively investigated,
primarily for tumor imaging application. This afﬁbody molecule
bindswith picomolar afﬁnity (22 pM) to the extracellular domain of
HER2 receptors [19].
Cellular processing studies have shown that internalization of
anti-HER2 afﬁbody molecules is relatively slow [20]. Typically, less
than 30% of the bound tracer was internalized after 24 h. Therefore,
the use of a residualizing radiometal label to increase radioactivity
retention in tumor cells is of less importance for the anti-HER2
afﬁbody molecule, because most of the retained activity is mem-
brane bound. However, similar to other small proteins and pep-
tides, efﬁcient tumor targeting was associated with signiﬁcant
renal accumulation of afﬁbody molecules labeled with residualiz-
ing radiometals such as 177Lu, 90Y, and 114mIn [21e23]. This accu-
mulation is attributed to extensive tubular reabsorption after
glomerular ﬁltration [24].
A high level of reabsorption exposes the kidneys to irradiation at
high doses, which would potentially compromise their function-
ality. An approach to reduce this high renal dose is fusing afﬁbody
molecules to a 46 amino acid albumin binding domain (ABD),
derived from streptococcal protein G. The non-covalent binding of
such afﬁbody-ABD fusion proteins to albumin in vivo was found to
prolong circulation times and reduce kidney accumulation [21,25].
However, long residence time of the conjugate in circulation may
result in higher irradiation of the very radiosensitive bone marrow.
On the contrary, afﬁbody molecules labeled with non-residualizing
labels provide rapid clearance of radioactivity from kidneys
without reducing tumor dose while avoiding long circulation times
[26].
Earlier, a series of studies involving labeling of afﬁbody mole-
cules with technetium-99m (99mTc) using peptide-based N3S che-
lators has been performed (for reviews concerning labeling with
technetium and rhenium radioisotopes, see Refs. [27e29]). These
studies demonstrated that targeting properties of labeled probes
can be improved by selecting an optimal chelator [30e36]. Sub-
stitution of the amino acids forming the chelator for binding 99mTc
had a profound effect on the biodistribution proﬁle of afﬁbody
molecules. Initially, the 99mTc-labeling of afﬁbody molecules was
performed using the mercaptoacetyl-glycyl-glycyl-glycyl (maGGG)
chelator coupled to the N-terminus of the anti-HER2 afﬁbody
molecule ZHER2:342 [37]. The tracer was capable of targeting HER2
in vivo, but underwent high hepatobiliary excretion. Combination
of serine (polar) and glutamic acid (charged) in mercaptoacetyl-containing chelators (maESE) provided a radiolabeled conjugate
with less hepatobiliary excretion and renal retention of radioac-
tivity [38]. To permit recombinant production, cysteine as the thiol-
bearing moiety was introduced on the C-terminus of the anti-HER2
afﬁbody molecule. The tracer 99mTc-ZHER2:2395-Cys (having KVDC
sequence at the C-terminus) demonstrated excellent bio-
distribution except from an elevated kidney uptake [34]. To reduce
the renal uptake, a GSEC chelator (a “mirror” C-terminal homolog of
maESE-) was designed [33]. The use of GSEC resulted in four-fold
reduction of renal retention in comparison with KVDC. For
further optimization of cysteine containing peptide-based chela-
tors, a series of recombinantly produced derivatives containing
GSEC, GGGC, GGSC, GGEC, or GGKC peptide chelators at the C-ter-
minus (designated as ZHER2:V1, ZHER2:V2, ZHER2:V3, ZHER2:V4 and
ZHER2:V5 respectively) was generated [35]. The in vivo evaluation of
the 99mTc-labeled variants demonstrated low hepatobiliary excre-
tion and rapid blood clearance. The renal retention varied consid-
erably, with the GGGC containing anti-HER2 afﬁbody molecule
showing the lowest kidney associated radioactivity (6.4 ± 0.6% ID/g
at 4 h p.i.). Further optimization showed that the order of amino
acids in the chelating sequence inﬂuenced renal uptake of some
conjugates at 1 h after injection, but the difference decreased at
later time points [36]. The results obtained with 99mTc-labeled anti-
HER2 afﬁbody molecules prompted us to utilize this experience in
developing an afﬁbody-based tumor-targeting agent for peptide-
based radionuclide therapy.
Rhenium is a chemical analogue of technetium, and two
rhenium isotopes, 186Re (T½ ¼ 3.72 days; Ebmax ¼ 1.08 MeV) and
188Re (T½ ¼ 17.0 h; Eb max ¼ 2.1 MeV), are considered suitable for
therapy. High-energy (188Re) or medium energy (186Re) b-particles
are well suited for eradication of both bulky non-operable tumors
and large metastases. The g-radiation of these nuclides (186Re:
Eg ¼ 155 keV,15%; 188Re: Eg ¼ 137 keV, 9%) enables in vivo imaging
of the biodistribution of rhenium-labeled conjugates, which could
be used for patient-speciﬁc dosimetry. At the same time, the g-
radiation would not contribute too much to the whole-body irra-
diation due to low abundance. The half-life of 188Re matches better
the rapid in vivo kinetics of afﬁbody molecules. In addition, 188Re is
produced using a 188W/188Re generator, which reduces the radio-
nuclide costs and facilitates the logistics of therapy. Furthermore,
this nuclide might be produced in a no-carrier-added state, with a
high speciﬁc radioactivity. Thus 188Re is an attractive label for
afﬁbody-based radionuclide therapy on the precondition that the
issue of renal accumulation is solved. Rhenium isotopes (mainly
188Re) have been used for RIT to eliminate large burdens of leuke-
mia in conjunction with standard preparative regimens prior to
stem cells transplantation [39,40]. Attempts to expand the thera-
peutic applications of rhenium, in order to include solid tumors,
had limited success. However, 188Re has been preclinically evalu-
ated as a label for, e.g., somatostatin analogues for treatment of
neuroendocrine tumors [41], a-melanocyte stimulating hormone
peptide analogs (a-MSH) for treatment of melanoma [42], water
soluble oligonucleotides (c-MORF) [43] and peptide-based haptens
for treatment of colorectal cancer using a pretargeting approach
[44].
Earlier, our group has reported 186Re-maGSG-ZHER2:342 as a po-
tential afﬁbody conjugate for therapy of HER2 expressing tumors
[45]. This conjugate had a low renal retention, but rather high de-
gree of hepatobiliary excretion. Dosimetry evaluation showed that
dose to tumor should exceed dose to normal tissues by several
folds. However, a high irradiation of the intestines was a major
concern and prompted us to further optimize the targeting prop-
erties and biodistribution proﬁle of the anti-HER2 afﬁbody mole-
cule for therapeutic application using rhenium isotopes.
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the amino acid sequences GGGC (ZHER2:V2), GGSC (ZHER2:V3), GGEC
(ZHER2:V4), GGKC (ZHER2:V5), GSGC (ZHER2:V6), GEGC (ZHER2:V7), and
GKGC (ZHER2:V8), as peptide-based chelators (Fig. 1) at the C-ter-
minus for labeling with 188Re. Evaluation included binding speci-
ﬁcity to HER2 receptors, afﬁnity determination, stability of the
conjugates and biodistribution proﬁle of the conjugates in normal
and tumor bearing mice. The parental anti-HER2 afﬁbody molecule
ZHER2:2395 containing a KVDC peptide-based chelator at the C-ter-
minus was used as a reference.2. Experimental section
2.1. Materials
D-gluconic acid sodium salt, ethylenediaminetetraacetic acid
(EDTA) and chloroquine disphosphate were from SigmaeAldrich,
tin(II)-chloride dihydrate (SnCl2  2H2O) and pyridine were from
Fluka Chemika. Phosphate buffered saline, pH 7.4 (PBS) was pro-
duced in house.188Re was obtained as perrhenate by elution of a
188W/188Re generator with 4 mL sterile 0.9% sodium chloride (both
from Polatom, Otwok-Poland). An automated g-counter with a
~7.6-cm (3-in) NaI(Tl) detector (1480 WIZARD; Wallac Oy) was
used to measure radioactivity. A Cyclone storage phosphor system
and OptiQuant image analysis software (both from PerkineElmer)
were used to measure the radioactivity on instant thin-layer
chromatography silica gel-impregnated (ITLC SG) strips. The afﬁ-
bodymolecule ZHER2:2395 was provided and puriﬁed by Afﬁbody AB.
The variants ZHER2:V2 to ZHER2:V8 were produced and puriﬁed using
a novel antiidiotypic puriﬁcation strategy, which has been devel-
oped earlier by Wållberg et al. [46]. Purity of all variants was above
95%. A description of some relevant properties of these variants is
presented elsewhere [35,36]. Data on cellular uptake and bio-
distribution were assessed by an unpaired, two-tailed Student's t-
test using GraphPad Prism (v 4.00 forWindows GraphPad Software,Fig. 1. Overview of the 188Re-labeled afﬁbody molecule variants evaluated in this study.
sequence aligned to the parent molecule ZHER2:342. The variable amino acids are marked in bo
N3S chelators formed by a C-terminal cysteine and three adjacent amino acids. R1 and R
radionuclide.San Diego, California, USA) in order to determine any signiﬁcant
differences (p < 0.05).
2.2. Labeling of afﬁbody molecules with 188Re
The cysteine-containing HER2-binding afﬁbody molecules were
site-speciﬁcally labeled with 188Re using freeze-dried labeling kits
each containing 5 mg of sodium gluconate, 100 mg of edetate
disodium (EDTA), and 1mg of tin(II) chloride dihydrate. The freeze-
dried kits were stored at 20 C.
Radiolabeling was performed by adding the contents of one
freeze-dried kit, dissolved in 1.25 M sodium acetate, pH 4.2, 100 mg
of each afﬁbody molecule up to a total volume of 100 mL. To the
reaction solution, 35 mL (3e4 MBq) of a 188Re-containing generator
eluate was added under argon gas. An equivalent of 220 mg ascorbic
acid (2 mg/mL in 1.25 M sodium acetate buffer, pH 4.2) was added
to the reaction vial and the mixture was incubated at 90 C for
60 min and then cooled at room temperature for 5 min. Thereafter,
the total amount of ascorbic acid in the reaction vial was adjusted to
be 1 mg using a solution of 5 mg/mL ascorbic acid in PBS containing
2% BSA. One mL samples were taken for analysis of the labeling yield
by ITLC SG with PBS as the mobile phase. The labeled conjugates
were puriﬁed using disposable NAP-5 columns (GE Healthcare)
pre-equilibrated with PBS, containing 2% BSA. The column was
eluted with 900 mL of the same solution. The ﬁnal solution was
further diluted with 100 mL PBS containing 2% BSA and 500 mg
ascorbic acid to a ﬁnal volume of 1 mL. After puriﬁcation, the purity
was evaluated using instant thin-layer chromatography.
2.3. In vitro studies
2.3.1. Binding speciﬁcity of radiolabeled afﬁbody molecules to
HER2-expressing cells in vitro
Binding speciﬁcity of eight 188Re-labeled variants was evaluated
using ovarian carcinoma SKOV-3 (1.6  106 receptors/cell) pur-
chased from American Type Tissue Culture Collection (ATCC). CellsA. The studied HER2-binding afﬁbody molecules including the C-terminal chelating
ld. Positions of a-helices 1 through 3 are indicated by boxes. B. General structure of the
2 and denote the side chains of the amino acids involved in the coordination of the
Table 1
Radiochemical yield and radiochemical purity of different anti-HER2 afﬁbody
molecules.
Variant Yield% Purity%
188Re-ZHER2:2395 89.3 ± 1.2 99.9
188Re-ZHER2:V2 95.8 ± 1 100
188Re-ZHER2:V3 96.6 ± 0.6 100
188Re-ZHER2:V6 97 ± 0.8 100
188Re-ZHER2:V4 98.2 ± 0.7 100
188Re-ZHER2:V7 95.8 ± 0.1 100
188Re-ZHER2:V5 96.5 ± 0.2 100
188Re-ZHER2:V8 96.5 ± 0.1 100
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dium (SigmaeAldrich) containing 10% fetal bovine serum. Brieﬂy, a
2 nM solution of each variant was added to six Petri dishes
(~1 106 cells/dish). For blocking, a 500-fold excess of non-labeled
recombinant ZHER2:2395 was added 5 min before the labeled con-
jugates to saturate the receptors. The cells were incubated during
1 h in a humidiﬁed incubator at 37 C. Thereafter, the media was
collected, the cells were detached by trypsin-EDTA solution and the
radioactivity in cells and media was measured to calculate the
percentage of cell-bound radioactivity.
2.3.2. Afﬁnity determination using LigandTracer
SKOV-3 cells were seeded on a local area of a cell culture dish
(NunclonTM, Size 100620, NUNC A/S, Roskilde, Denmark), as
described previously [47]. The binding of 188Re-labeled anti-HER2
afﬁbody molecules to living cells was monitored in real-time us-
ing LigandTracer Yellow, using established methods [47]. To sup-
press internalization of afﬁbody-HER2 complex, measurements
were performed at 4 C. By using the TraceDrawer software, which
allows the calculation of both association and dissociation rate, it
becomes possible to determine the afﬁnity of radiolabeled conju-
gate [47]. In order to cover the concentration span needed for
proper afﬁnity estimation, two concentrations of 49 pM and 98 pM
(selected based on previous KD values obtained using Biacore) of
each variant were added in each afﬁnity assay.
2.3.3. Cellular retention of 188Re elabeled afﬁbody molecules by
HER2 expressing ovarian carcinoma (SKOV-3) cells
Cellular retention was studied using the methods validated for
afﬁbody molecules earlier [20]. SKOV-3 cells (1  106 cells/dish)
were incubated with 2 nM solution of labeled afﬁbody at 4 C. After
1 h incubation, the medium with the labeled compound was
removed and cells were washed three times with ice-cold serum-
free medium. One mL of complete media was added to each dish
and cells were further incubated at 37 C in an atmosphere con-
taining 5% CO2. At designated time points (4 h and 24 h), a group of
three dishes was removed from the incubator, the media was
collected and cells were washed three times with ice-cold serum-
free medium. Thereafter, cells were detached by trypsin-EDTA so-
lution and the radioactivity in cells and media was measured to
calculate the percentage of cell-bound radioactivity from total
added.
2.4. In vivo studies
The animal experiments were planned and performed in
accordance with national legislation on laboratory animal protec-
tion. The animal study plans have been approved by the local Ethics
Committee for Animal Research in Uppsala.
Biodistribution studies were performed in female immuno-
competent Naval Medical Research Institute (NMRI) mice. All mice
were acclimatized for 1 week at the Rudbeck Laboratory animal
facility before any experimental procedures. Sixty four mice with
an average weight of 30 g were randomized into groups of four
animals each. Animals were injected intravenously with 1 mg
(120 kBq) conjugate per animal in 100 mL PBS containing 2% BSA.
One group of mice was euthanized at each predetermined time
point (1 and 4 h after injection) by an intraperitoneal injection of
anesthesia, KetalareRompun solution (20 mL/g body weight;
Ketalar: 10 mg/mL, Pﬁzer; Rompun[xylazine]: 1 mg/mL) with
subsequent exsanguination by heart puncture using a 1 mL syringe
prewashed with diluted heparin (5000 IU/mL). Blood, lung, liver,
spleen, stomach, kidney, salivary glands, muscle, bone, intestines,
and the remaining carcass were collected. Organs and tissue sam-
ples were weighed, and their radioactivity was measured. Thetissue uptake values were calculated as percent of injected dose per
gram tissue (%ID/g) except for the intestines and the carcass, which
were calculated as %ID per whole sample.
In vivo imaging was performed to obtain a visual conﬁrmation of
the biodistribution data. Three NMRI mice were injected with
0.7 MBq (8 mg) of 188Re-ZHER2:2395 (-KVDC), 188Re-ZHER2:V4 (-GGEC)
and 188Re-ZHER2:V2 (-GGGC) respectively. Mice were sacriﬁced by
cervical dislocation at 4 h after injection. The imaging experiment
was performed using an Inﬁnia g-camera (GE Healthcare) equipped
with a High-energy general purpose (HEGP) collimator. Static im-
ages (30 min) were obtained with a zoom factor of 2 in a 256  256
matrix.
The 188Re-labeled conjugates with the lowest and highest up-
take in normal organs, 188Re-ZHER2:V2 (-GGGC) and 188Re-ZHER2:2395
(-KVDC), respectively, was used in a tumor targeting study with the
aim of determining tumor and kidney accumulation of radioac-
tivity. A total of eight Balb/C nude mice (average weight 19 g) were
subcutaneously injected with 1  107 HER2-expressing SKOV-3
cells in the left ﬂank. Three weeks after implantation the tumors
were 3 mm [3] in size and mice were randomized in to two groups
(n ¼ 4). Each group was injected intravenously with either 188Re-
ZHER2:V2 (-GGGC) or 188Re-ZHER2:2395 (-KVDC) (total protein dose
5 mg per animal, about 90 kBq in 100 mL PBS containing 2% BSA).
Mice were sacriﬁced at 4 h p.i. and previously mentioned organs in
addition to the tumors were collected, weighed, and their radio-
activity was measured. For speciﬁcity control, one additional group
(n ¼ 4) was pre-injected with 500 mg of ZHER2:342 45 min before
injection of 188Re-ZHER2:V2 to saturate HER2 receptors in tumors.
The animals were sacriﬁced at 4 h p.i., and uptake in blood and
tumors was measured.3. Results
3.1. Labeling
All afﬁbody molecules were efﬁciently labeled with 188Re by
transchelation from gluconate.
Data concerning the labeling yield and radiochemical purity of
ZHER2:2395 and the eGXYC variants; ZHER2:V2 to ZHER2:V8, are pre-
sented in Table 1. The labeling yields exceeded 95% for all variants
except ZHER2:2395 for which the labeling yield was 89.3 ± 1.2%. The
radiochemical purity of the labeled products after puriﬁcation us-
ing NAP-5 columns was above 99% for all the eight conjugates.3.2. Binding to HER2-expressing cells in vitro
All conjugates showed speciﬁc binding to the HER2 receptor as
the uptake by SKOV-3 cells was signiﬁcantly (p-value < 5  104)
reduced by pre-saturation with 500-fold molar excess of unlabeled
protein.
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body molecules binding to HER2-expressing SKOV-3 cells in vitro
using LigandTracer conﬁrmed that high afﬁnity to HER2 was pre-
served after labeling. Evaluation of data by ﬁtting the binding and
dissociation curves to a 1:1 interaction model indicates that the
binding of radiolabeled conjugates to living HER2-expressing cells
is mediated by single binding site populations. This 1:1 interaction
is in agreement with previously obtained Surface Plasmon Reso-
nance (SPR) analysis data performed on a Biacore 2000 instrument
(GE Healthcare) [36]. The dissociation constants at equilibrium (KD)
for binding of radiolabeled afﬁbodymolecules to the HER2 receptor
are shown in Table 2. All variants demonstrated high afﬁnity in the
low picomolar range. Fig. 2 shows the KD measurement sensogram
for 188Re-ZHER2:V2.
The composition of the peptide-based chelators had an
apparent inﬂuence on the cellular retention of the 188Re-labeled
conjugates after binding to HER2-expressing SKOV-3 cells
(Fig. 3).188Re-ZHER2:2395 and 188Re-ZHER2:V5 (both containing the
positively charged amino acid lysine) showed the highest overall
retention compared to the other variants, 188Re-ZHER2:V3 (-GGSC)
and 188Re-ZHER2:V4 (-GGEC) containing a polar and a negatively
charged amino acid, respectively, showed moderate overall reten-
tion after 24 h. 188Re-ZHER2:V2 (-GGGC) with no polar or charged
residues had the lowest overall retention both at 4 and 24 h.
Moreover, ZHER2:V6 (-GSGC), ZHER2:V7 (-GEGC) and ZHER2:V8 (-GKGC)
showed an appreciable difference from the levels of cellular
retention obtained for their counterparts with GGXC chelators
(ZHER2:V3, ZHER2:V4 and ZHER2:V5). In general, the GXGC-containing
conjugates were less efﬁciently retained by HER2 expressing cells.3.3. In vivo studies
To determine the in vivo uptake of radioactivity in different or-
gans, the radiolabeled constructs were injected into female NMRI
mice. Data concerning biodistribution 1 and 4 h p.i, are presented in
Table 3. For comparison, data of the GXGC and GGXC-containing
counterparts are provided in the form of pairs. All comparative
ﬁndings reported are statistically signiﬁcant unless otherwise
stated. All eight studied 188Re-labeled constructs, ZHER2:2395,
ZHER2:V2, ZHER2:V3, ZHER2:V6, ZHER2:V4, ZHER2:V7, ZHER2:V5 and ZHER2:V8
showed a rapid blood clearance, which is typical for afﬁbody
molecules. The blood-associated radioactivity was reduced 5e8.2-
fold between 1 and 4 h after injection. A low level of radioactivity
in the gastrointestinal tract (with its content) suggested that hep-
atobiliary excretion did not play a substantial role. No signiﬁcant
differences in radioactivity were observed in organs that rapidly
establish an equilibrium with the blood pool (spleen and salivaryTable 2
The dissociation constants KD of interaction of rhenium-
188 labeled afﬁbody molecules with HER2-expressing
SKOV-3 cells determined using LigandTracer at 4 C.
Afﬁnity determination using ligand tracer
Variant KD (pM)
188Re-ZHER2:2395 10.6 ± 0.6
188Re-ZHER2:V2 6.4 ± 0.4
188Re-ZHER2:V3 51 ± 3
188Re-ZHER2:V6 4 ± 1
188Re-ZHER2:V4 10 ± 6
188Re-ZHER2:V7 21 ± 10
188Re-ZHER2:V5 5 ± 2
188Re-ZHER2:V8 <13 pMa
a Accurate measurement of off-rate was not possible
despite 6 h long measurement due to very slow
dissociation.glands). All other non-excretory organs displayed similar uptake
proﬁles of the different afﬁbody variants.
Overall, the analysis demonstrated a strong inﬂuence of the
compositionof the peptide-based chelator and the relative positions
of amino acids on the biodistribution. Most obvious was the inﬂu-
ence on uptake in liver, lung and kidneys (Fig. 4). It is apparent that
the lysine containing variants 188Re-ZHER2:2395 (KVDC), 188Re-
ZHER2:V5 (GGKC) and 188Re-ZHER2:V8 (GKGC)were retained to a higher
extent in the excretory organs in comparison to other variants.
Moreover, changing the position of a single amino acid on the
peptide based chelator from GGXC to GXGC resulted in a signiﬁ-
cantly lower retention in the liver (1.44 ± 0.06 %ID/g for ZHER2:V3 vs.
0.7 ± 0.1%ID/g for ZHER2:V6, 1.3 ± 0.3 %ID/g for ZHER2:V4 vs. 0.8 ± 0.1 %
ID/g for ZHER2:V7 and 3.3± 0.5%ID/g for ZHER2:V5 vs. 2.4± 0.1 %ID/g for
ZHER2:V8) and kidneys (20 ± 4 %ID/g for ZHER2:V3 vs. 10 ± 1 %ID/g for
ZHER2:V6, 31 ± 6 %ID/g for ZHER2:V4 vs. 23 ± 2 %ID/g for ZHER2:V7 and
152± 24%ID/g for ZHER2:V5 vs.136± 23%ID/g for ZHER2:V8) at 4 h after
injection. A somewhat elevated lung uptake of 188Re-ZHER2:V4 was
observed both at 1 and 4h after injection (3.2±0.8 and 1.0±0.3 %ID/
g respectively), compared to the other variants. This elevated pul-
monary uptake has been observed earlier for 99mTc-labeled ZHER2:V4
at 4 hp.i. [35]. Throughout the study the variant, 188Re-ZHER2:V2,with
the C-terminal chelating sequence eGGGC, provided the lowest
radioactivity retention in all organs including the kidneys (3.1 ± 0.5
%ID/g 4 h p.i.) and liver (0.33 ± 0.05 %ID/g 4 h p.i.).
A comparative imaging study using 188Re-ZHER2:2395, 188Re-
ZHER2:V4 and 188Re-ZHER2:V2 respectively conﬁrmed the bio-
distribution results (Fig. 5). Images obtained at 4 h after injection
showed no visible uptake in any organ except from kidneys. The
intensity of kidney visualization varied between 188Re-ZHER2:2395
(strong) and 188Re-ZHER2:V4 (moderate). The kidneys were barely
visible when mice were injected with 188Re-ZHER2:V2.
To evaluate inﬂuence of chelators on tumor targeting, we per-
formed a comparative biodistribution study between 188Re-
ZHER2:V2 and 188Re-ZHER2:2395 in female NMRI nu/nu mice bearing
subcutaneous SKOV-3 ovarian carcinoma xenografts. The mice
were sacriﬁced at 4 h after injection. Data are presented in Table 4.
The data of normal organs uptake is in excellent agreement with
those obtained in normal NMRI mice (Tables 3 and 4). Moreover,
efﬁcient tumor targeting has been demonstrated. The tumor uptake
of 188Re-ZHER2:V2 (18.7 ± 2.8 %ID/g) exceeded by far the uptake in
any other organ or tissue. Tumor uptake exceeded kidney uptake by
5-fold at this time point. As expected, the radioactivity concentra-
tion of 188Re-ZHER2:2395 exceeded that of 188Re-ZHER2:V2 in many
organs, especially the kidneys (196 ± 38 vs. 3.4 ± 0.3 %ID/g,
respectively) and liver (2.5 ± 0.54 vs. 0.40 ± 0.01 %ID/g, respec-
tively). The overall tumor-to-organ ratios are presented in Table 4
for comparison. To evaluate in vivo speciﬁcity of HER2 targeting
using 188Re-ZHER2:V2, HER2 receptors in tumors were saturated in a
group of mice by pre-injection of large excess of non-labeled
parental ZHER2:342 afﬁbody molecule. Tumor uptake in this group
was 2.2 ± 1.8 %ID/g, which is signiﬁcantly (p < 0.05) lower than
uptake in the non-blocked group (18.7 ± 2.8 %ID/g). The blood
concentration (0.18 ± 0.04 %ID/g) did not differ signiﬁcantly from
the concentration in the non-blocked group. The results of this
experiment demonstrate saturability of HER2 targeting in vivo and
suggest its speciﬁcity.
4. Discussion
High renal reabsorption of afﬁbody molecules is the major issue
in development of conjugates for radionuclide therapy. The use of
residualizing labels results in that the a renal uptake is exceeding
the tumor uptake by 15e20 fold, which makes radionuclide ther-
apy non-feasible [16,34,48]. One approach for the development of
Fig. 2. Sensorgram of 188Re-ZHER2:V2 dissociation constants at equilibrium (KD) for binding of radiolabeled afﬁbody molecules to HER2 expressing SKOV-3 cells using LigandTracer
Yellow with two different concentrations at 4 C.
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Fig. 3. Inﬂuence of the amino acid composition and their position in the cysteine-containing chelators on the cellular retention of 188Re-labeled afﬁbody molecules by SKOV-3 cells.
A. retention of 188Re-ZHER2:2395 (-KVDC), 188Re-ZHER2:V2 (-GGGC), 188Re-ZHER2:V3 (-GGSC), 188Re-ZHER2:V3 (-GSGC); B. retention of 188Re-ZHER2:V4 (-GGEC), 188Re-ZHER2:V7 (-GEGC), 188Re-
ZHER2:V5 (-GGKC), 188Re-ZHER2:V8 (-GKGC).
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afﬁbody molecules by tumor cells (slow internalization) and by cell
in proximal tubuli in kidneys (rapid internalization). The use of
non-residualizing labels provides a rapid clearance of radioactivity
from kidneys but slow release from tumors due to a high afﬁnity to
the target. This permits obtaining higher radioactivity concentra-
tion in tumors than in kidneys and should thus make radionuclide
therapy using afﬁbody molecules possible [26,45]. Previous studies
have demonstrated that the composition of cysteine-containing
peptide-based chelators might be used for modulation of renal
uptake of 99mTc and provided higher uptake in tumors than in
kidneys [35,36]. The chemical similarity between Re and Tc creates
a potential for translation of this approach to the development of
therapeutic targeting agents. However, the properties of rhenium
and technetium are not identical, and substituting 99mTc with
rhenium radioisotopes might appreciably inﬂuence the blood
clearance rate, as well as the uptake and retention in excretory
organs and other tissues [41,45]. This necessitates a re-evaluation of
the inﬂuence of peptide-based chelators on the uptake and reten-
tion of 188Re-labeled afﬁbody molecules in liver and kidneys.
Peptide-based cysteine-containing chelators are directly engi-
neered into the afﬁbody molecules by genetic insertion of peptide-encoding gene fragments, and the constructs can be produced in
high yield in prokaryotic hosts, i.e. E. coli. No further conjugation
step is thus required, which simpliﬁes the process and reduces
costs. The labeling is site-speciﬁc, which is important to provide a
uniform radiolabeled product with reproducible physicochemical
and biological properties. This is essential, as our previous studies
have demonstrated that the position of the chelators noticeably
inﬂuences the biodistribution and targeting properties of 99mTc-
labeled afﬁbody molecules [32].
Generally, labeling with rhenium requires much higher con-
centration of reducing agents than labeling with technetium, and
thus harsher labeling conditions [41]. These conditions are gener-
ally non-compatible with proteins that are dependent on disulﬁde
bonds, such as antibodies and antibody fragments. To overcome
this, an indirect two-step process was developed for labeling of
antibodies where rhenium is ﬁrst chelated by N3S chelator in harsh
conditions, and then the chelator is conjugated to an antibody
[49e52]. Multiple steps increase probability of labeling failure and
reduces yield. The use of peptide-based chelators permits high-
yield labeling (Table 1) of afﬁbody molecules with 188Re in the
presence of gluconate as an exchange ligand. Currently, the labeling
is performed using a two-vial kit, but it is amenable to development
Table 3
Biodistribution of188Reelabeled afﬁbodymolecules in female NMRImice, 1 and 4 h after intravenous injection. Themeasured radioactivity of different organs is expressed as %
ID/g, and presented as an average value from 4 animals ± SD.
188Re-ZHER2:2395
(-KVDC)
188Re-ZHER2:V2
(-GGGC)
188Re-ZHER2:V3
(-GGSC)
188Re-ZHER2:V6
(-GSGC)
188Re-ZHER2:V4
(-GGEC)
188Re-ZHER2:V7
(-GEGC)
188Re-ZHER2:V5
(-GGKC)
188Re-ZHER2:V
(-GKGC)
1 h
Blood 1.0 ± 0.1 1.18 ± 0.08 1.31 ± 0.06 1.6 ± 0.1 1.1 ± 0.3 1.5 ± 0.1 1.2 ± 0.1 1.15 ± 0.12
Lung 1.5 ± 0.1 1.9 ± 0.2 2.1 ± 0.2 2.5 ± 0.2 3.2 ± 0.8 2.0 ± 0.2 2.47 ± 0.45 2.0 ± 0.2
Liver 2.57 ± 0.25 1.3 ± 0.1 2.0 ± 0.2 2.0 ± 0.1 1.8 ± 0.3 1.9 ± 0.2 3.2 ± 0.8 2.6 ± 0.2
Spleen 0.7 ± 0.2 0.53 ± 0.04 1.0 ± 0.2 1.1 ± 0.2 1.0 ± 0.3 0.8 ± 0.1 1.25 ± 0.18 1.07 ± 0.07
Stomach 0.9 ± 0.1 1.3 ± 0.3 1.38 ± 0.15 2.0 ± 0.2 1.3 ± 0.4 1.5 ± 0.1 2.2 ± 0.6 1.42 ± 0.15
Kidney 148 ± 13 26 ± 6 94 ± 8 68 ± 7 129 ± 21 121 ± 18 150 ± 19 146 ± 8
Salivary
gland
0.6 ± 0.1 0.7 ± 0.05 0.8 ± 0.2 1.0 ± 0.1 0.9 ± 0.3 0.9 ± 0.1 1.3 ± 0.3 0.85 ± 0.1
Muscle 0.30 ± 0.03 0.33 ± 0.02 0.40 ± 0.02 0.38 ± 0.02 0.35 ± 0.05 0.4 ± 0.1 0.4 ± 0.05 0.4 ± 0.1
Bone 1.1 ± 0.1 0.9 ± 0.3 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.2 1.1 ± 0.2 1.16 ± 0.25 0.9 ± 0.2
Carcassa 9.7 ± 1.3 10 ± 0.3 11 ± 1.0 14 ± 1.3 10.6 ± 1.6 12 ± 1.0 11.3 ± 0.8 10.2 ± 0.5
GI tracta 3.4 ± 0.3 1.5 ± 0.2 1.9 ± 0.3 2.18 ± 0.35 1.6 ± 0.2 1.8 ± 0.1 2.1 ± 0.2 1.9 ± 0.2
4 h
Blood 0.14 ± 0.04 0.15 ± 0.03 0.28 ± 0.05 0.20 ± 0.02 0.2 ± 0.1 0.18 ± 0.05 0.19 ± 0.05 0.20 ± 0.06
Lung 0.5 ± 0.1 0.24 ± 0.09 0.66 ± 0.07 0.40 ± 0.03 1.0 ± 0.3 0.4 ± 0.1 1.0 ± 0.2 0.8 ± 0.1
Liver 2.23 ± 0.46 0.33 ± 0.05 1.44 ± 0.06 0.7 ± 0.1 1.3 ± 0.3 0.8 ± 0.1 3.3 ± 0.5 2.45 ± 0.12
Spleen 0.5 ± 0.1 0.16 ± 0.03 0.5 ± 0.1 0.33 ± 0.08 0.47 ± 0.15 0.3 ± 0.1 0.8 ± 0.4 0.8 ± 0.1
Stomach 0.55 ± 0.15 0.5 ± 0.3 1.0 ± 0.4 0.7 ± 0.2 0.6 ± 0.4 0.33 ± 0.03 1.5 ± 0.5 0.75 ± 0.20
Kidney 172 ± 32 3.1 ± 0.5 20 ± 4.0 10 ± 1.0 31 ± 6 23 ± 2 152 ± 24 136 ± 23
Salivary
gland
0.4 ± 0.1 0.29 ± 0.16 0.56 ± 0.05 0.55 ± 0.06 0.42 ± 0.20 0.25 ± 0.02 0.80 ± 0.35 0.65 ± 0.12
Muscle 0.11 ± 0.01 0.05 ± 0.01 0.13 ± 0.04 0.07 ± 0.02 0.09 ± 0.03 0.06 ± 0.01 0.15 ± 0.03 0.12 ± 0.01
Bone 0.8 ± 0.3 0.22 ± 0.05 0.3 ± 0.1 0.21 ± 0.05 0.34 ± 0.07 0.26 ± 0.03 0.6 ± 0.2 0.47 ± 0.04
Carcassa 3.4 ± 0.5 1.8 ± 0.4 4.1 ± 0.5 2.7 ± 1.2 2.82 ± 0.55 2.3 ± 0.2 5.3 ± 0.9 4.2 ± 0.8
GI tracta 3.1 ± 0.2 1.89 ± 1.45 1.7 ± 0.6 2.6 ± 0.8 2.5 ± 1.5 1.6 ± 0.5 1.8 ± 0.3 1.4 ± 0.8
a Data for gastro-intestinal tract with content and carcass are presented as % of injected radioactivity per whole sample.
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procedure [53]. In addition to the small size and rapid kinetics of
afﬁbody molecules, their tolerance to harsh labeling conditions
(robustness) is a major advantage over immunoglobulin-based
targeting agents. All the eight 188Re-labeled afﬁbody molecules
bound to HER2-expressing cells with high (low picomolar) afﬁnity
(Table 2).
The amino acids adjacent to cysteine had a clear effect on the
cellular processing of 188Re-labeled afﬁbody molecules. The cellular
retention was the highest for lysine-containing chelators, followed
by glutamate- and serine-containing ones (Fig. 3). For each pair of
homologous chelators, the GGXC variants (where X ¼ K, E or S)
provided better retention of radioactivity than the GXGC counter-
parts (Fig. 3). This pattern was in excellent agreement with our
earlier data concerning cellular processing of 99mTc-labeled vari-
ants [36]. As afﬁnities of binding to HER2-expressing cells were
very similar for all variants (Table 2), the difference in cellular
retention was, most likely, due to difference in cellular processing
of radiocatabolites after internalization and lysosomal degradation.
This is supported by close resemblance of retention proﬁles of
188Re-ZHER2:V2 and 188Re-ZHER2:V3 with the proﬁle of the parental
afﬁbody labeled with non-residualizing radioiodine labels [54],
while retention pattern of 188Re-ZHER2:2395, 188Re-ZHER2:V5 and
188Re-ZHER2:V8 was similar to the proﬁle of afﬁbody molecules
labeled with residualizing 111In [48]. Despite the lower retention by
SKOV-3 cells, the biological half-life of 188Re-ZHER2:V2 and 188Re-
ZHER2:V3 was about 15 h, which corresponds well with retention of
radioactivity delivered by afﬁbody molecules with non-
residualizing radiohalogen labels to HER2-expressing tumors
in vivo [26,54].
In vivo data suggest rapid clearance of all conjugates from blood
(Table 3). The radioactivity uptake in the gastrointestinal tract (with
content) was low, typically less than 2% of injected radioactivity.
This suggests that the hepatobiliary pathway played a minor role, if
any, in the excretion of the conjugates or their radiometabolites.The radioactivity uptake in Na/I symporter expressing organs,
stomach and salivary gland, was also low. Since these organs
accumulate radioperrhenate [55], the low uptake indicates that
there was no loss of the radionuclide in vivo due to re-oxidation of
188Re. Uptake in muscle and bone was also low, and variation be-
tween conjugates was not substantial. However, the retention of
constructs with lysine-containing chelators (i.e. 188Re-ZHER2:2395,
188Re-ZHER2:V5 and 188Re-ZHER2:V8) was signiﬁcantly higher than
others. The most apparent was the difference in uptakes in lungs,
liver, and kidneys (Fig. 4). Uptake of radioactivity at 4 h p.i. was
signiﬁcantly higher for constructs with GGXC variants (where X¼ E
or S) than for GXGC in lung and kidneys. For liver, this was true also
for lysine-containing chelators.
The uptake of 188Re-ZHER2:V2 (with GGGC chelator) was lower in
all these organs than the uptake of constructs with chelators con-
taining polar or charged side chains. The most striking was the
difference in the renal uptake. The renal uptake of 188Re-ZHER2:V2
was 2.5e6 fold lower than uptake of other conjugates already at 1 h
p.i. At 4 h p.i., the renal uptake of 188Re-ZHER2:V2 was 40e50 fold
lower than the uptake of constructs with lysine-containing chela-
tors (188Re-ZHER2:2395, 188Re-ZHER2:V5 and 188Re-ZHER2:V8). Overall,
the pattern of the radioactivity retention in kidneys resembled the
pattern of cellular retention of the same constructs by SKOV-3 cells,
i.e. the ranking of conjugates according to their retention was the
same, but the magnitude of the variance was different. Most likely,
this difference can be explained by that the internalization rate of
afﬁbody molecules in kidneys is much higher than in tumor cells.
After re-absorption from primary urine in proximal tubuli, afﬁbody
molecules should be degraded in lysosomes. The further fate of
radiorhenium depends of physiochemical properties of the radio-
catabolites. Most likely, radiocatabolites of 188Re-ZHER2:V2 leak
directly into urine, as biodistribution of this agent does not show
any site of their possible re-uptake. This creates preconditions for
successful targeted radionuclide therapy of HER2-expressing tu-
mors using 188Re-ZHER2:V2.
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Fig. 5. g-camera imaging of mice injected with188Re -labeled ZHER2:2395, ZHER2:V2 and ZHER2:V4 at 4 h p.i. Visualization of kidneys was only possible with ZHER2:2395 (A) and ZHER2:V4 (B)
while it was impossible with ZHER2:V2 (C). (K) kidneys, (B) bladder.
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Table 4
Comparative biodistribution of188Re-ZHER2:V2 and188Re-ZHER2:2395 in female NMRI
nu/nu mice bearing subcutaneous SKOV-3 xenografts at 4 h after intravenous in-
jection. The uptake values are presented as an average value from 4 animals ± SD.
188Re-ZHER2:V2 188Re-ZHER2:2395
Uptake, %
ID/g
Tumor-to-organ
ratio
Uptake, %
ID/g
Tumor-to-organ
ratio
Tumor 18.7 ± 2.8b 11.4 ± 4.5
Blood 0.20 ± 0.15 92 0.22 ± 0.1 53
Lung 0.39 ± 0.01 48 0.8 ± 0.38 14
Liver 0.40 ± 0.01b 46 2.5 ± 0.54 5
Spleen 0.22 ± 0.05b 84 0.97 ± 0.18 12
Stomach 0.37 ± 0.1 51 0.7 ± 0.25 16
Kidney 3.4 ± 0.30b 5 196 ± 38 0.06
Salivary
gland
0.26 ± 0.03b 70 0.61 ± 0.15 19
Muscle 0.09 ± 0.03 210 0.12 ± 0.01 92
Bone 0.21 ± 0.04b 87 0.58 ± 0.10 20
Carcassa 2.9 ± 0.62 4.1 ± 0.9
GI tracta,b 0.8 ± 0.12 2.2 ± 0.3
a Data for gastro-intestinal tract with content and carcass are presented as % of
injected radioactivity per whole sample.
b Signiﬁcant difference (p < 0.05) between 188Re-ZHER2:V2 and 188Re-ZHER2:2395.
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very similar to the biodistribution of their 99mTc-labeled counter-
parts studied earlier [35,36]. However, there were some noticeable
differences. For example, the uptake of 188Re-ZHER2:V2 was lower in
liver and spleen at 4 h p.i. than the uptake of 99mTc-ZHER2:V2. On the
other hand, the uptake of 188Re-ZHER2:V3 was higher in lung, liver,
spleen, stomach and salivary gland than the uptake of 99mTc-
ZHER2:V3. Despite their chemical similarity, rhenium and technetium
labels have different inﬂuence on biodistribution of labeled afﬁ-
body molecules, necessitating careful structure-properties rela-
tionship studies for each label.
The biodistribution of 188Re-ZHER2:V2 in mice bearing HER2-
expressing tumor xenografts (Table 4) demonstrated that tumor
uptake at 4 h after injection appreciably exceeded uptake in any
other organs. In vivo blocking experiment demonstrated HER2
speciﬁcity of targeting SKOV-3 xenografts using 188Re-ZHER2:V2.
Uptake in blood and bone, which are associated with bone marrow
suppression, were 90-fold lower than the tumor uptake. Renal
uptake was 5-fold lower that the uptake in tumors. This suggests
that 188Re-ZHER2:V2 can efﬁciently target HER2-expressing tumors
and justiﬁes its further development as a targeting agent for
radionuclide therapy.
Earlier, we have studied synthetically produced anti-HER2 afﬁ-
body molecules, maGGG-ZHER2:342 and maGSG-ZHER2:342 labeled
with 186Re on the N-terminus [45]. Both 186Re- maGGG and 186Re-
maGSG with non-residualizing labels provided low retention of
radioactivity in kidneys, making radionuclide therapy possible.
However, the placement of the label at the C-terminus in the cur-
rent study resulted in a 10-fold reduction of hepatobiliary excretion
of radioactivity, which reduces the dose to the radiosensitive in-
testines. Thus, 188Re-ZHER2:V2 is a better format for afﬁbody mole-
cules aimed for therapy.
In conclusion, 188Re-ZHER2:V2 provides lower retention of radio-
activity in kidneys, and is a promising candidate for radionuclide
therapy of HER2-expressing tumors. This study, along with other
studies on afﬁbody molecules, suggests that an optimal labeling
strategy permits not only a stable attachment of a radionuclide to a
targeting scaffold protein, but also allows for optimization of bio-
distribution and targeting properties of the radioconjugate.Acknowledgment
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